Skip to main content
OpenTrials
Completed

NCT Number: NCT05146089

Reflex Responses to Intermittent Hypoxia in Humans: Mechanisms and Consequences

The overall goal of this project is to better understand the effect of intermittent hypoxia (IH) on sympathetic neuronal discharge patterns in humans, as well as mechanisms that mediate persistent sympathoexcitation with IH.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–45 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Early Phase 1

Primary location

University of Missouri-Columbia, Columbia, Missouri, United States

Loading trial locations.

About this study

Sleep apnea is the most common form of sleep disordered breathing and patients with sleep apnea exhibit persistent activation of the sympathetic nervous system. Sympathoexcitation is also the final common pathway for a host of complications in conditions like obesity, hypertension, sleep apnea, and heart failure and plays a significant role in predicting negative clinical outcomes and deteriorating cardiovascular health. However, the mechanisms of sympathoexcitation with sleep apnea are poorly understood and thus make effective therapeutic approaches difficult to develop.

Intermittent hypoxia (IH) has been implicated in animal models as the primary stimulus for evoking increases in sympathetic activity with recurrent apneas. Thus, the overall goal of this application is to better understand the effect of IH on sympathetic discharge patterns in humans as well as the mechanisms mediating persistent sympathoexcitation with IH. By better understanding the effect of IH on sympathoexcitation, targeted therapeutic approaches might be devised to mitigate the effects of sympathetic over-activity on the cardiovascular system in conditions such as sleep apnea.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • healthy adult men and women;
  • 18-45 years of age;
  • BMI <30 kg/m2;
  • non-pregnant/non-breastfeeding;
  • non-smokers.

Exclusion criteria

Subjects will be excluded if they are:

  • taking any medications known to affect the cardiovascular or autonomic nervous system (e.g. alpha-blockers, beta-blockers, etc);
  • Apnea Hypopnea Index >10 events/hr

Self-reported history of:

  • hepatic, renal, pulmonary, cardiovascular, or neurological disease;
  • stroke or neurovascular disease;
  • bleeding/clotting disorders;
  • sleep apnea or other sleep disorders;
  • diabetes;
  • smoking;
  • history of alcoholism or substance abuse;
  • hypertension.

Treatment and study plan

Hypoxic exposure

Other

30 minutes of intermittent hypoxia achieved using breaths of low oxygen air (5% oxygen) followed by room air through a mask.

modified Oxford test

Other

An intravenous bolus of sodium nitroprusside (100 μg) will be given to decrease blood pressure, followed 1 minute later by a bolus of phenylephrine (150 μg) to increase blood pressure, occurring before and after intermittent hypoxia exposure.

Oral Bosentan 62.5 mg

Drug

Prior to completion of visit 2, male subjects will consume 62.5 mg twice daily for 3 days as well as the morning of the study visit (7 pills) at home and experimental sessions will be performed 3 hours after oral intake of the final dose.

Hypoxic ventilatory response test

Other

Hypoxia will be achieved using breaths of low oxygen air (5% oxygen) followed by room air through a mask. This will be repeated 4-5 times per test, occurring before and after intermittent hypoxia exposure.

Primary outcomes

  1. Muscle sympathetic nerve activity (MSNA)

    Time frame: Change from baseline after hypoxia exposure

    MSNA burst incidence (bursts/100 heart beats)

Secondary outcomes

  1. Arterial blood pressure

    Time frame: Change from baseline after hypoxia exposure

    Systolic blood pressure, Diastolic blood pressure, Mean blood pressure

Sponsors and collaborators

Lead sponsor

University of Missouri-Columbia

Other

Collaborators

  • Mayo Clinic
  • National Heart, Lung, and Blood Institute (NHLBI)

Registry information

Important dates

Study start
2016
Primary completion
2018
Study completion
2021
First posted
Dec 6, 2021
Registry last updated
Dec 6, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.